Jun 3, 2022 Efficacy proof-of-concept from a phase 1 study of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ in patients with refractory solid tumors
Apr 11, 2022 Characterizing the PK/PD relationship of C/EBPβ antagonist peptide ST101 in a mouse orthotopic breast cancer model
Sep 16, 2021 Efficacy, safety, pharmacokinetic and pharmacodynamic data from phase 1 dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients with advanced and metastatic solid tumors
Apr 9, 2021 Tumor uptake and dose-proportional PK of ST101 - a peptide antagonist of C/EBPβ – in patients with advanced unresectable and metastatic solid tumors
Jun 22, 2020 β-catenin antagonist peptide attenuates oncogenic gene transactivation and promotes antitumor activity in breast cancer models
Jun 22, 2020 C/EBPβ antagonist peptide, ST101, attenuates oncogenic gene transactivation in cancer cells to drive antitumor activity
Apr 1, 2019 Cell penetrating peptide, ST101, disrupts ATF5 regulation of anti-apoptotic Bcl-2 family proteins, resulting in induction of cancer cell death in vitro and tumor growth inhibition/regression in vivo
